- Home
- NCSM vs MGNX Comparison
NCSM vs MGNX Comparison
Compare NCSM & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCSM
- MGNX
- Stock Information
- Founded
- NCSM 2006
- MGNX 2000
- Country
- NCSM United States
- MGNX United States
- Employees
- NCSM N/A
- MGNX N/A
- Industry
- NCSM Oilfield Services/Equipment
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- NCSM Energy
- MGNX Health Care
- Exchange
- NCSM Nasdaq
- MGNX Nasdaq
- Market Cap
- NCSM 61.1M
- MGNX 70.3M
- IPO Year
- NCSM 2017
- MGNX 2013
- Fundamental
- Price
- NCSM $31.44
- MGNX $1.43
- Analyst Decision
- NCSM
- MGNX Hold
- Analyst Count
- NCSM 0
- MGNX 10
- Target Price
- NCSM N/A
- MGNX $6.83
- AVG Volume (30 Days)
- NCSM 9.5K
- MGNX 602.8K
- Earning Date
- NCSM 04-30-2025
- MGNX 05-20-2025
- Dividend Yield
- NCSM N/A
- MGNX N/A
- EPS Growth
- NCSM N/A
- MGNX N/A
- EPS
- NCSM 3.27
- MGNX N/A
- Revenue
- NCSM $168,704,000.00
- MGNX $149,962,000.00
- Revenue This Year
- NCSM $7.03
- MGNX N/A
- Revenue Next Year
- NCSM $5.82
- MGNX $80.86
- P/E Ratio
- NCSM $9.66
- MGNX N/A
- Revenue Growth
- NCSM 18.16
- MGNX 155.26
- 52 Week Low
- NCSM $15.90
- MGNX $0.99
- 52 Week High
- NCSM $38.95
- MGNX $14.91
- Technical
- Relative Strength Index (RSI)
- NCSM 52.40
- MGNX 43.37
- Support Level
- NCSM $29.15
- MGNX $1.54
- Resistance Level
- NCSM $32.71
- MGNX $1.82
- Average True Range (ATR)
- NCSM 1.84
- MGNX 0.15
- MACD
- NCSM 0.26
- MGNX 0.01
- Stochastic Oscillator
- NCSM 38.99
- MGNX 19.79
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc provides products and support services that facilitate the optimization of oil and natural gas well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's primary offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. Geographically, majority of revenue is generated from United States.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.